Cited by 21Alzheimer's disease research and treatmentsCellular transport and secretionMicrotubule and mitosis dynamics

DYRK1A Regulates the Bidirectional Axonal Transport of APP in Human-Derived Neurons

Open access
Fernandez Bessone, Iván, Navarro, Jordi, Martinez, Emanuel, Karmirian, Karina, Holubiec, Mariana, Alloatti, Matias, Goto-Silva, Livia, Arnaiz Yepez, Cayetana +6 more·2022·The Journal of Neuroscience

Published version of a preprint

Abstract

Dyrk1a triplication in Down9s syndrome and its overexpression in Alzheimer9s disease suggest a role for increased DYRK1A activity in the abnormal metabolism of APP. Transport defects are early phenotypes in the progression of Alzheimer9s disease, which lead to APP processing impairments. However, whether DYRK1A regulates the intracellular transport and delivery of APP in human neurons remains unknown. From a proteomic dataset of human cerebral organoids treated with harmine, a DYRK1A inhibitor, we found expression changes in protein clusters associated with the control of microtubule-based transport and in close interaction with the APP vesicle. Live imaging of APP axonal transport in human-derived neurons treated with harmine or overexpressing a dominant negative DYRK1A revealed a reduction in APP vesicle density and enhanced the stochastic behavior of retrograde vesicle transport. Moreover, harmine increased the fraction of slow segmental velocities and changed speed transitions supporting a DYRK1A-mediated effect in the exchange of active motor configuration. Contrarily, the overexpression of DYRK1A in human polarized neurons increased the axonal density of APP vesicles and enhanced the processivity of retrograde APP. In addition, increased DYRK1A activity induced faster retrograde segmental velocities together with significant changes in slow to fast anterograde and retrograde speed transitions, suggesting the facilitation of the active motor configuration. Our results highlight DYRK1A as a modulator of the axonal transport machinery driving APP intracellular distribution in neurons, and stress DYRK1A inhibition as a putative therapeutic intervention to restore APP axonal transport in Down9s syndrome and Alzheimer9s disease. SIGNIFICANCE STATEMENT Axonal transport defects are early events in the progression of neurodegenerative diseases, such as Alzheimer9s disease. However, the molecular mechanisms underlying transport defects remain elusive. Dyrk1a kinase is triplicated in Down9s syndrome and overexpressed in Alzheimer9s disease, suggesting that DYRK1A dysfunction affects molecular pathways leading to early-onset neurodegeneration. Here, we show by live imaging of human-derived neurons that DYRK1A activity differentially regulates the intracellular trafficking of APP. Further, single-particle analysis revealed DYRK1A as a modulator of axonal transport and the configuration of active motors within the APP vesicle. Our work highlights DYRK1A as a regulator of APP axonal transport and metabolism, supporting DYRK1A inhibition as a therapeutic strategy to restore intracellular dynamics in Alzheimer9s disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2551-21.2022

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DYRK1A overexpression may influence initial AD progression through mechanisms including hyperphosphorylation of tau, APP, PS1, regulation of axonal transport of APP, and participation in selective splicing of tau pre-mRNA.

    “Given that overexpression of dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) may influence the initial progression of AD through mechanisms including the hyperphosphorylation of pathologically relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA,500–502”

    From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [501]

    The Introduction reports DYRK1A-related phosphorylation of APP and tau, and the Discussion reports that DYRK1A overexpression changes axonal APP transport. The cited paper does not substantiate PS1 phosphorylation or discuss DYRK1A’s participation in selective tau pre-mRNA splicing beyond listing a related study in its References. No page numbers are provided in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fernandez Bessone, I., Navarro, J., Martinez, E., Karmirian, K., Holubiec, M., Alloatti, M., Goto-Silva, L., Arnaiz Yepez, C., Martins-de-Souza, D., Minardi Nascimento, J., Bruno, L., Saez, T. M., Rehen, S. K., & Falzone, T. L.
Affiliations
  • Universidad de Buenos Aires (AR)
  • Universidade Federal do Rio de Janeiro (BR)
  • Max Planck Society (DE)
Venue
The Journal of Neuroscience
Published
2022-07-08
Volume
42
Issue
33
Pages
6344-6358
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W4284968170
Cited by
21
References
66
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 3
FWCI
2.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
International Brain Research Organization
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
Keywords
DYRK1A, amyloid precursor protein, axonal transport, retrograde transport, anterograde transport, harmine, Down syndrome, Alzheimer's disease, microtubule transport, brain organoids, single-particle tracking, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review